bioAffinity Technologies, Inc. 8-K

What Happened
bioAffinity Technologies, Inc. (BIAF) filed a Form 8-K on January 7, 2026 (Item 8.01) reporting that its wholly owned laboratory subsidiary, Precision Pathology Laboratory Services, successfully maintained its accreditation from the College of American Pathologists (CAP) following an on-site inspection. The company attached a press release covering the announcement as Exhibit 99.1.

Key Details

• Date filed: January 7, 2026 (Form 8-K, Item 8.01).
• Subsidiary: Precision Pathology Laboratory Services (wholly owned by bioAffinity).
• Accreditation: Maintained accreditation from the College of American Pathologists (CAP) after an on-site inspection.
• Press release: Issued January 7, 2026 and included as Exhibit 99.1 to the 8-K.

Why It Matters
Maintaining CAP accreditation affirms that Precision Pathology meets recognized quality and laboratory practice standards. For investors, this supports the subsidiary’s operational credibility and regulatory compliance—factors that help preserve the lab’s ability to perform and report clinical tests without interruption. The filing is informational and does not disclose financial impacts, but it signals ongoing adherence to industry standards that underpin laboratory services.